The uptake of metallic nanoparticles in breast cancer cell lines is modulated by the HA-CD44 axis.

Marie Hullo[1,2#], Cécile Mathé[1,2#], Nuria Fonknechten[1,2], Céline Lallemand[1,2], Guillaume Piton[1,2,3], Johanna Noireaux[4], Sylvie Chevillard[1,2], Anna Campalans[1,2], Emmanuelle Bourneuf[1,2*]

[1]Université Paris-Saclay, CEA/DRF/IBFJ/IRCM. UMR Stabilité Génétique Cellules Souches et Radiations, F-92260 Fontenay-aux-Roses, France

[2]Université Paris-Cité, CEA/DRF/IBFJ/IRCM. UMR Stabilité Génétique Cellules Souches et Radiations, F-92260 Fontenay-aux-Roses, France

[3]Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, F-92260 Fontenay-aux-Roses, France

[4]Environment and Climate Change Department, National Metrology and Testing Laboratory (LNE), Paris, France.

Co-first authors

* Corresponding author

Keywords: TiO_2 and Au nanoparticles, breast cancer, mesenchymal cells, epithelial cells, hyaluronan, CD44

ABSTRACT

Radio-enhancement is a promising anti-cancer approach based on a local radiation dose increase due to the presence of metallic nanoparticles (NPs) within cancer cells. Depending on their composition, size and cellular properties, NPs can follow multiple cellular pathways and entry routes. We observed that gold, platinum and TiO_2 NPs are internalized at higher levels in mesenchymal cells compared to epithelial cells in breast cancer models. A global survey of gene expression between epithelial and mesenchymal cells exposed to 4 different NP types revealed an involvement of membrane structure, and further experiments confirmed that the hyaluronic acid (HA) and its receptor CD44 are mediators of metallic NP uptake into cells. We extended our results to a larger panel of breast cancer cell lines and again showed a preferential uptake of all NPs tested in mesenchymal cells and relying on the HA/CD44 axis. These data provide new considerations for the design of NP-based therapies targeting mesenchymal cancer cells, which are often resistant to treatment and correlate with poor prognosis and tumor recurrence.

INTRODUCTION

Nanomaterials, *ie* elements which size ranges from a few to 100nm, represent promising tools for clinical applications. Current developments in cancer research focus notably on nanoparticles (NPs) as drug carriers targeting specific cell types, or as sensitizers of radiotherapy (RT). The physicochemical properties of nano-sized objects can be exploited for designing multimodal theranostic nanoparticles, allowing for example imaging and radiosensitization simultaneously. Although being one of the pillars of current cancer treatment, radiotherapy can induce severe secondary effects when healthy tissues surrounding the tumors receive too much ionizing radiation. In addition, cancer cells radioresistance, which can be intrinsic or acquired during treatment, also prevents the successful elimination of all cancer cells[1]. The development of new radiotherapy modalities (beam design, type of particle, for example) as well as the identification of radiosensitizing or radioenhancing molecules is crucial to keep an efficient tumor control while sparing healthy surrounding tissues, and therefore improve the global therapeutic index of RT[2]. Nanoparticle-enhanced radiotherapy relies on the use of high-Z metallic nanoparticles, which presence in cells will increase the probability of interaction between incident photons and matter[3]. In addition to direct effects of radiations on structures, the massive release of secondary electrons will enhance radiolysis of water molecules, ROS production and subsequent damages to biological molecules, such as DNA, lipids and proteins[4]. Ultimately, damage to organelles and DNA will lead to cell death. In addition, in vivo experiments on mouse tumor models injected with hafnium-based NBTXR3 nanoparticles successfully demonstrated the activation of immune response towards cancer cells, suggesting a systemic effect of local radiation dose enhancement[5]. Overall, this approach consisting on a local dose escalation could improve the therapeutic ratio by allowing a global dose de-escalation and healthy tissue sparing, while maintaining an efficient tumor cell killing.

The first *in vivo* proof of concept of nanoparticle-based enhanced radiotherapy was established by Hainfeld in 2004, in an animal model of mammary carcinoma[6]. Since this

seminal study, many nanoparticle designs, conjugating different metal compositions and surface modifications, have successfully been used as radiosensitizers in mouse models[7,8], and a few have reached clinical trials.

An optimal radiation enhancement ratio can be achieved with a maximal uptake of the metallic nanoparticles within cells[9]. In general, the particle uptake can be achieved by passive transport, or actively by endocytosis. Endocytosis groups phagocytosis, clathrin and caveolae-mediated endocytosis, and other pathways[10]. Of course, the NP uptake is highly dependent on NPs physico-chemical features, such as size, shape, charge and corona composition[11]. Regarding NP size, permeation will be favored for very small NPs (under 5 nm), while active endocytosis will be used for larger NPs. Therefore, NPs are often functionalized with ligands or other molecules that can target membrane-bound receptors and lead to a specific cellular uptake. Several very comprehensive reviews have discussed NP uptake via different endocytic pathways, as well as methodological approaches and pitfalls that often lead to misinterpretation[9–11].

Studies specifically focusing on metallic NPs larger than 10nm have hypothesized different modes of uptake, generally by classical endocytosis. However, cell type variability and NP-cell interactions are underestimated factors. Yet tumors represent heterogeneous entities, composed of a complex interplay of many cell types, such as cancer, immune, stromal cells, etc. While cellular heterogeneity offers new treatment opportunities by targeting immune populations for example, the plasticity and dynamic adaptation of cancer cells is critical. For example, when stimulated by growth factors or chemotherapeutic drugs, cells can undergo profound phenotypic and genetic changes, in a process called epithelial-to-mesenchymal transition (EMT). EMT fosters extravasation and metastatic invasion, as well as therapeutic resistance[12]. In breast cancer, mesenchymal or partially mesenchymal (hybrid) cells, albeit in small numbers, are considered to be the most resistant and invasive and are thought to be responsible for a substantial amount of tumor relapses[13].

To better understand the uptake of nanoparticles in cancer cells, we interrogated various metallic NPs entry in a panel of breast cancer cell lines representing epithelial and mesenchymal phenotypes. A transcriptomic survey allowed to refine the molecular mechanisms explaining that metallic NPs uptake is higher in mesenchymal cells, showing that hyaluronan and CD44 are involved. Finally, the findings were extended to a broader panel of cell lines, including models of breast cancer EMT, highlighting that the HA/CD44 pathway is hijacked by metallic NPs and that this observation could be exploited for therapeutic purposes.

RESULTS

Metallic nanoparticles are differentially internalized across breast cancer cell lines

Numerous cell models are available for breast cancer studies, among which T47D and MDA-MB-231 are frequently used to compare features that could differ between epithelial and mesenchymal like cells. Indeed, T47D cells exhibit a polarized epithelial like phenotype, with a cuboid shape, markers of cell-cell interaction and adhesion, such as E-cadherin (E-cad) and desmosomes and a molecular phenotype CD24+/CD44-/E-cad+ (**Figure 1.A**). In contrast, MDA-MB-231 cells are spindle-shaped, highly motile and express genes involved in stem cell features (ZEB1, VIM, α5β1 integrin...), as well as molecular markers CD24-/CD44+/E-cad-. Interestingly, those cells also show a differential resistance to drugs and radiation. Epithelial cells are sensitive to treatments and die mostly by apoptosis, while mesenchymal cells undergo cell cycle arrest but eventually start proliferating again. We wondered how these features would have an effect on radioenhancement approaches, starting with their ability to uptake NPs within cells. Taking advantage of physicochemical properties of metallic NPs to observe or quantify them, we investigated their uptake and localization within both T47D and MDA-MB-231 models.

The two cell types were first exposed to 32nm gold nanoparticles (AuNPs – **Supplementary Table 1**) for 72h, and the cells were observed by dark-field microscopy. AuNPs were clearly

detected at 72h exposure, in both cell models, with however more nanoparticiles in the MDA-MB-231 cells (**Figure 1.B.**). Unfortunately, this type of detection is not precise enough to quantify and localise the AuNPs within the cells. In order to objectively measure the amount of gold internalized by the cells, the intracellular gold mass was measured by ICP-MS, 24 hours after exposure to 32µg/cm² of AuNPs (**Figure 1.C**). The absolute amount of gold found in MDA-MB-231 cells corresponded to an average of 0.1 pg/cell, while in T47D cells it was about half. Thus, AuNPs are internalized in both cell lines, and their intracellular levels appear to be different. Next, the uptake of other metallic nanoparticles was tested in the same cell lines to exclude an effect only attributable to gold NPs. The amount of intracellular TiO_2 NPs (NM-100, with a size of 110nm**, Supplementary Table 2**) was evaluated by flow cytometry, after 24h exposure to the NPs and two washes to avoid a potential bias due to membrane-bound NPs. The measure of side scatter signal (SSC) deviation, although not perfectly quantitative, is a convenient proxy for the evaluation of TiO_2 NPs and AgNPs (silver NPs) cellular uptake[14,15]. The results are shown in **Figure 1.D.**, where an increase in the SSC deviation can be observed in both cell lines, proportional to the TiO_2 NPs concentration. Again, a higher uptake was observed in MDA-MB-231 compared to T47D cells. Finally, in a previous report we showed an equivalent result for PtNPs (platinum NPs) internalized in MDA-MB-231 and T47D cells[16]. As early as after 2h of exposure, PtNPs accumulate in structures resembling mutivesicular bodies, providing insight into the subcellular localization of PtNPs. The ICP-MS method further demonstrated a higher mass of platinum in MDA-MB-231 compared to T47D cells.

Taken together, these results showed a concentration and time-dependent uptake of several types of NPs in two breast cancer cell lines. Furthermore, MDA-MB-231 cells internalized a higher amount of NPs compared to T47D cells, irrespective of the NP.

Since T47D and MDA-MB-231 cells are derived from tumours excised from different patients, the observed difference could be due to variable pathways or metabolic alterations between the cells. Therefore, it seems important to test such an observation in cellular models

with the same genetic background. Therefore, we took advantage of two epigenetic models, namely HMLE[17] and MCF10A cells[18], which illustrate the breast epithelial-mesenchymal transition *in vitro*. Both cell types initially exhibit an epithelial-like phenotype with $CD24^+/CD44^-$ labelling, and express high levels of E-cadherin (**Figure 2.A.**). HMLE-E and MCF10A-E cells can undergo a reversible epithelial to mesenchymal transition when exposed to chronic doses of EMT inducer, here TGFβ (Transforming Growth Factor – β). The mesenchymal cells obtained (HMLE-M and MCF10A-M) show a mesenchymal phenotype, with $CD24^-/CD44^+$ markers and a morphological type that is more fusiform and proliferating (**Figure 2.A.**).

To evaluate the effect of EMT status in NP uptake, we use TiO2 NPs of two different sizes (NM100 - size 110 nm and NM103 - size 25nm). As can be observed in F**igure 2.B.**, the SSC-A deviation showed a gradual increase in signal, proportional to the concentration of the NM-100 suspension. In addition, the uptake in HMLE-M was higher than in HMLE-E cells for all concentrations studied. In another experiment investigating the impact of cell confluence on uptake, a higher deviation in HMLE-M than HMLE-E cells was also observed. In addition, while a higher uptake was evidenced at lower cell densities, the difference between epithelial and mesenchymal remained significant (**Supp Fig 1**). Other experiments also showed that the cell surface difference between HMLE-E and M cells was barely significant at high confluence (data not shown). Thus, although cell confluence can have a tremendous impact on cell behaviour, especially in these epigenetic transition models, our results show that metallic NPs uptake is consistently different between epithelial and mesenchymal cells. Regarding MCF10A cells, the SSC-A deviation was 50% higher in MCF10A-M compared to MCF10A-E cells, upon exposure to a fixed concentration of NM100 and NM103 TiO_2 nanoparticles **(Figure 2.C.**). These results show that both MCF10A and HMLE epigenetic models internalize more metallic nanoparticles when they are in their mesenchymal form.

To summarize, we show that a differential pattern of internalization exists between breast cancer cells, and that this difference is reproducible even with NPs harbouring different properties, such as a various range of sizes. In addition, in all tested conditions, uptake was more important in mesenchymal cell lines compared to epithelial ones, regardless of confluence or genetic background.

Transcriptomic analysis of a differential uptake of nanoparticles between epithelial and mesenchymal cells

To explore the pathways involved in the differential internalization of nanoparticles, HMLE epithelial and mesenchymal cells were exposed to several NPs and gene expression profile was analyzed using microarrays. The use of the HMLE model overcomes potential interference due to the genetic background of the cell lines. Four different types of gold and TiO_2 NPs were selected with the objective of finding common molecular mechanism to the uptake of NPs of variable size, coating, charge and composition (as mentioned in Table 1). HMLE-E and HMLE-M cells were exposed to a NP concentration of 16µg/cm² for 24 or 48hours. Differential gene expression was further analysed taking into account only genes modified homogeneously across nanoparticles and timepoints, thus indicating candidates that could explain a consistent difference in NPs uptake between epithelial and mesenchymal cells. A list of 597 differentially expressed genes was obtained (s**upplementary table 4**), and **tables 2** and **3** show the most overexpressed genes in mesenchymal and epithelial cells, respectively. In both cases, the experiment revealed genes that are usually highly expressed in the specific epithelial and mesenchymal breast cancer cells, and found in many other studies. For example, *ZEB1* (FC=57.4, p-val=$1.3x10^{-13}$) and *SERPINE1* (FC=64.57, p-val=$5.7x10^{-13}$), overexpressed in mesenchymal cells, are markers of EMT[19,20]. Conversely, expression of *EPCAM* (FC=1609, p-val=$5.06x10^{-19}$), *ESRP1* (FC=1162, p-val=$6.79x10^{-16}$), and *CDH1* (FC=90, p-val=$3.62x10^{-14}$),

is not surprisingly much higher in epithelial cells. The corresponding proteins, such as E-cadherin, are frequently used as molecular markers of an epithelial state[19].

This global analysis again showed that the epithelial/mesenchymal status of the exposed cells governs the entry of metallic NPs, without highlighting a precise pathway. Thus in order to gain more insight into the common genes involved in NP uptake, we investigated the pathways and functions attributed to the 597 genes. Data mining was performed using a GSEA analysis. Table 4 reports the Hallmarks categories obtained from our data. Estrogen response (early and late) and KRAS signaling are more expressed in epithelial cells, whereas an EMT signature and hypoxia features are found in mesenchymal cells. The analysis based on REACTOME shows an enrichment in keratinization and cornification features, both indicators of epithelial cells, while mesenchymal associated categories concern extracellular matrix organization, glycosylation, and glycosaminoglycans (**Table 5**).

The comparison of our data with Chemical and Genetic perturbations database reveals an enrichment in signatures from breast cancer and epithelial to mesenchymal transition (**Figure 3A and Table 6**). For example, the ONDER_CDH1_TARGETS signature (down in E cells, and up in M cells) comes from a study by Onder *et al*[21], where CDH1 expression was inhibited in HMLER cells (HMLE cells transformed with Ras oncogene), inducing an epithelial-mesenchymal transition. Thus, our data fit well with this HMLER cellular model used for understanding mechanisms governing the EMT program. Similarly, Charafe-Jauffret *et al* have produced signatures corresponding to differential expression between luminal, basal and mesenchymal cells[22]. Our data reveal luminal/basal features in E cells and mesenchymal ones in M cells. The stem cell signature by Boquest *et al*[23] and Lim *et al*[24] follows the same pattern, with a higher expression of corresponding genes in M cells compared to the E cells. In addition to a mesenchymal phenotype, Bontemps *et al* recently described the stem cells properties of HMLE-M cells[25] .

Finally, Enrichment analysis was conducted on Gene Ontology categories (**Table 7**). For the Cell Component ontology analysis, our data indicate again a pattern of epithelial cells in negatively regulated genes (basolateral/apical parts, cell-cell junctions, etc...) whereas most signatures present in M cells are focused on Extracellular matrix (ECM) and synaptic space **(Figure 3B**). ECM is also found in Molecular Function class, where the top classes identified concern ECM structural components, glycosaminoglycan binding and ion binding (e.g. zinc and calcium). Finally, Biological Process confirms the epithelial pattern in E cells (epidermal development and differentiation, cell-cell junctions). For M cells, we found a TGFβ response signature and several features related to organ development.

Overall, these data suggest that typical epithelial and mesenchymal cell signatures are conserved upon nanoparticle exposure. However, among those features, there was a particular enrichment for ECM and cell membrane. Although this aspect seems obvious regarding the process of NP uptake, it indicates that the difference in uptake between E and M cells is mainly due to membrane and matrix differences between the cell types, and not to intracellular differences that could interfere. Indeed, one might have expected a large differential expression of intracellular vesicular transport or even transcription factors involved in E/M difference. Furthermore, no specific endocytic pathway was highlighted by the analysis of these expression data, thus rather suggesting that the mechanism of uptake we were looking for did not involve a specific route of endocytosis, and that the mechanism should correspond to a marked difference in membrane or ECM between E and M cells.

One of the major differences between E and M cells at the membrane level is the expression of the CD44s molecule, which is highly specific and considered one of the most relevant molecular markers for distinguishing epithelial from mesenchymal cells in breast cancer. CD44 (Cluster of differentiation 44) is a glycosylated transmembrane protein encoded by 19 exons. The standard form (CD44s) consists of the first 5 exons corresponding to the hyaluronan-binding domain, and the 4 last exons of the locus encoding the cytoplasmic domain. Other

isoforms are encoded with a combination of variable exons (v2 to v10). In the litterature, the expression of CD44s is predominant in mesenchymal breast cell lines (MDA-MB-231, MDA-MB-436, MCF10A), while the V2-10 isoform is mostly expressed in more epithelial cells (MCF7, BT474, ZR-75)[26].

CD44 is not differentially expressed in the transcriptome data since the probes present on the microarray do not discriminate the *CD44s* isoform (specific for M cells) from the other *CD44* isoforms. However, CD44s is commonly used in breast cancer research, to identify and sort mesenchymal cells from patient tumours or *in vitro* models (e.g. with HMLE and MCF10A cells, **Fig2A**). Hyaluronic acid (HA), one of the CD44 ligands, is synthesised by HAS (Hyaluronic Acid Synthases) enzymes[27]. In our data, *HAS2* is more expressed in M than in E cells (**Table 2**, FC=16.5, p-val=6.63×10^{-12}), which could indicate a more important production of hyaluronic acid in mesenchymal cells, as was already described for breast cancer cells[28]. Taken together, these results indicate a possible upregulation of the CD44s/HAS2/HA axis in M cells.

Evidence of the HA-CD44 axis role

To confirm the potential role of CD44-HAS2 in the uptake of NPs in our models, *CD44s* expression was measured in the 4 breast cancer cell lines, i.e. T47D, MDA-MB-231, HMLE-E and HMLE-M. As expected, *CD44s* expression, the « standard » form of CD44, was 10 times higher in HMLE-M than in HMLE-E, and 800 times more abundant in MDA-MB-231 cells compared to T47D (**Figure 4.A.**). Conversely, *CD44v2-10* isoform expression was 50-foldhigher in the epithelial form of HMLE cells, and 6-foldhigher in T47D compared to MDA-MB-231 cells (**Figure 4.B**). In order to evaluate the potential direct role of CD44 in NP uptake, HMLE-M and MDA-MB-231 cells were transduced with lentiviral particles encoding a shRNA targeting *CD44*, with no isoform specificity. Epithelial cell lines were not included since the *CD44s* basal expression of these cell lines is very low. Reduced expression of *CD44s* and

CD44v isoforms with the shRNA against CD44 was confirmed in both cell lines compared to a scramble shRNA coding vector (**Figure 4.C.**). The MDA-MB-231 cell line with a downregulation of *CD44* was further exposed to NM100 and NM103 TiO_2 nanoparticles for 24 hours. The uptake of TiO_2 NPs by the cells was evaluated by flow cytometry (**Figure 4.D.**) in three independent experiments. The uptake of NP was significantly reduced in cells transduced with the shRNA against CD44 compared to the scramble shRNA used as a control.

Hyaluronic Acid Synthases (*HAS1*, *2* and *3*) control the production and export of HA of different sizes on the extracellular side of the membrane[27]. HA is a high molecular weight molecule that binds notably to the extracellular domain of CD44. As *HAS1* expression was very low in all cell lines tested, we did not investigate the expression difference further. *HAS2* shows a clear differential pattern, with low to absent expression in epithelial lines (T47D, HMLE-E) and a much higher expression (>100 fold) in mesenchymal cell lines (**Figure 5.A.**). In contrast, *HAS3* was expressed in all cell lines, with a higher expression in HMLE-E and T47D than in HMLE-M and MDA-MB-231 cell lines (**Figure 5.B.**). However, HAS3 was not differentially expressed in the transcriptome data of NP-exposed cells, thus reinforcing the choice of HAS2 as a good candidate for further investigation.

In order to evaluate if HAS enzymes were functional in the cell lines studied, we used fluorescence microscopy to detect Hyaluronic Acid Binding Protein (HABP) and thus estimate the amount of HA at the cell surface. Cells were fixed and incubated with biotinylated HA-binding proteins, and further with fluorescently labeled streptavidin **(Figure 5.C.).** Microscopy analysis unveiled a different pattern of HA distribution, with a stronger signal at cell membranes in MDA-MB-231 cells compared to T47D cells. Similar results were obtained with the HMLE model. In agreement, quantification of HABP fluorescence signals by flow cytometry confirmed a more abundant HA labelling on the surface of mesenchymal cells compared to epithelial cells. (**Figure 5.D**).

To validate the involvement of HA in NP uptake, HA content was modified by treating cells with hyaluronidase prior to exposure to nanoparticles (**Figure 5.E**). In epithelial T47D cells, no effect of the hyaluronidase treatment was observed. In contrast, enzymatic digestion of HA on MDA-MB-231 cells significantly reduced NM100 and NM103 TiO_2 NP uptake. There results further confirm that HA coating facilitates NP uptake in mesenchymal cells. All these data converge towards a model of opportunistic entry of metallic NPs into cells via their interaction with HA and endocytosis by CD44s.

Metallic NP uptake via HA and CD44 is a general mechanism shared by mesenchymal breast cancer cell lines

In an attempt to generalize our observations to a larger panel of breast cancer cell lines, we measured *CD44s* RNA expression in 6 epithelial lines (T47D, SKBR3, BT20, MCF7, HMLE-E and MCF10A-E) and 5 mesenchymal lines (MDA-MB-231, MDA-MB-436, SUM159, HMLE-M and MCF10A-M). Again *CD44s* expression was at least 10 fold higher in mesenchymal compared to epithelial cells (**Figure 6.A.**). As mentioned above, breast epithelial and mesenchymal cells are generally phenotyped by the CD24 and CD44 labelling. Therefore flow cytometric phenotyping was conducted on 6 breast lines (not previously phenotyped, **Figure 6.B.**), confirming a higher expression of CD44s in mesenchymal cells.

Next, *HAS2* expression was measured in the same cell lines, also indicating a higher quantity of *HAS2* mRNAs in mesenchymal models (**Figure 7.A.**). A labeling of HA with the HABP-streptavidin-biotin-FITC system confirmed by flow cytometry that HA was more abundant in mesenchymal cell lines compared to epithelial ones (**Figure 7.B.).** Next, fluorescence microscopy showed a stronger HABP signal at cell membrane in mesenchymal cells compared to epithelial lines (**Figure 7.C.**).

To determine the amount of NPs internalized in the cells from the panel of lines, all cell lines were exposed to 110 or 25 nm size TiO_2 NPs, (NM100, **Figure 8.A.** and NM103, **Figure 8.B**.), and the SSC-A deviation was analysed after 24h of exposure. Despite some overlap, epithelial cell lines globally internalize less NPs than mesenchymal ones. Flow cytometry, as already mentioned, cannot be considered as a perfect method of quantification. Thus, absolute quantification of metal amount was measured with the ICP-MS method. Briefly, titanium and gold masses were quantified in cells exposed for 24h to TiO_2 NPs (**Figure 8.C.**) or AuNPs (**Figure 8.D.**). For each type of NPs, the amount internalized in mesenchymal cells was higher than in epithelial cells, confirming again, the existence of a differential uptake linked to the phenotype of the cells.

DISCUSSION

In addition to NP physicochemical characteristics, cell parameters can have a dramatic impact on NP internalization. Cellular models and culture conditions such as cell density have been shown to influence uptake[29]. Other aspects, such as impact of cell cycle phase, are more controversial and are at least partly due to cell size modification consequent to progression through the cell cycle. A simulation study has confirmed that the cell cycle does not play a role in NP uptake heterogeneity[30]. The genetic identity of cells also has an impact on endocytosis processes: for example, KRAS-mutant breast cancer cells have a higher NP uptake than wild-type cells, which is largely explained by a difference in macropinocytosis capacity of the cells[31]. In addition, the reliability and reproducibility of the results are also very dependent on the methods used to study uptake. Indeed, cellular models, NP preparations, and analytical methods can be very heterogeneous from one study to another, and may introduce bias. One of the main methods used to characterize endocytic processes is the incubation of cells with specific inhibitors. However, several groups have warned about the non specificity of those molecules, the loss in activity for some of them in the presence of serum and the use of poorly standardized protocols often leading to misinterpretations[32],[33]. We performed toxicity assays that revealed the toxicity of many of the classical inhibitors (nocodazole, dynasore, chlorpromazine) on our cellular models (data not shown), as already described by Sousa de Almeida *et al*[11]. Considering these limitations and in order to have a larger view of this complex question, we decided here to evaluate the uptake of different types of metallic nanoparticles in several independent cellular models and by using multiple complementary methodological approaches.

In this report as well as in previous research[16], we noticed a systematic larger uptake of metallic NPs in mesenchymal compared to epithelial breast cancer cells. To try to explain this difference in internalization and to avoid NP-linked biases, we performed a transcriptome analysis using four different NP suspensions. The analysis only included genes that were differentially expressed between epithelial and mesenchymal cells with a similar pattern among

all NPs. As expected, most significant genes corresponded to epithelial-mesenchymal transition, but interestingly, the analysis revealed an enrichment in membrane-related phenomena and functions, suggesting that endocytosis could be the main process explaining the difference observed. The data did not allow the identification of a single major mechanism involving particular receptors as could be revealed in some studies[34]. Instead, it suggests a potentially more universal pathway used by non-decorated NPs, although not exclusive for NP internalization. Remarkably, the transcriptome analysis highlighted HAS2 as one of the most differential genes, and our data also showed a differential expression of CD44s between epithelial and mesenchymal cell lines (Figures 4 and 5). Finally, we could evidence the presence of hyaluronan at the cell surface of mesenchymal cells, while it appears mainly cytoplasmic in epithelial cells (Figures 5 and 7). Therefore, we focused on the hyaluronan-CD44 interaction, since hyaluronan synthesis and specific alternative splicing of CD44 are known markers of EMT in breast cancer.

While we were carrying out this study, Rodriguez team published two major studies showing that iron, copper and other metals could interact with hyaluronic acid, and further be internalized in cells via the recycling of HA bound to CD44[35,36]. Muller *et al.* showed that iron is internalized to a greater extent in mesenchymal HMLER $CD44^{high}$ cells compared to more epithelial CD44 knock-out cells[36]. These observations are consistent with our hypothesis according to which metallic NPs would be taken up preferentially by cells with a more active HA-CD44 axis. A more recent study from the same group confirmed the involvement of this axis for other metals such as copper [35]. In 2024, Tsai *et al* showed a preferential uptake of FePt NPs in mesenchymal cells, through HA-CD44 as well[37]. In addition, several groups have described a differential amount of hyaluronan between epithelial and mesenchymal cells, and Udabage *et al*[38] have demonstrated that the daily turnover of HA is faster in MDA-MB-231 cells than in T47D cells. In this report we could demonstrate that the inhibition of CD44s, as

well as a hyaluronidase treatment, lead to a decrease in metallic NP uptake, in several cell models (Figures 4 and 5). Together with the literature, our results focusing on different metals and NP sizes demonstrate a general mechanism for uptake of metallic nanoparticles in cancer cells.

A few studies including genome-wide approaches have been reported in the last years, interrogating corona proteins or cellular receptors involved in multiple types of nanoparticles endocytosis. Thus, LDL Receptor, SLC46A3 and SCARB1 were identified as receptors able to facilitate NP uptake within cellular models, either binding known corona proteins[39] or by regulating lysosome transport[40]. Interestingly, Montizaan *et al.*[34] identified, in addition to the above-mentioned roles of LDLR and SCARB1, that glycosaminoglycans, and more precisely heparan sulfate metabolism, is also involved and provides a route for internalization of NPs.

Our study highlighted the role of hyaluronan, another glycosaminoglycan (GAG), in metallic NP uptake. Furthermore, our transcriptome analysis revealed that several GO categories corresponding to GAG metabolism (GAG_METABOLISM, Heparan_Sulfate METABOLISM, Chondroitin_sulfate _dermatan_sulfate METABOLISM) are found significantly enriched in mesenchymal cells compared to epithelial cells when exposed to NPs (Table 5).

Interestingly, other cellular models exhibit differential NP uptake. In the study of Pannico *et al*, both uptake kinetics and amount of AuNPs was higher in prostate cancer cells compared to non-cancerous epithelium cell line[41]. Guglielmi *et al* and Costanzo *et al* showed a higher uptake of PLGA (Poly lactic-co-glycolic acid) and mesoporous silica NPs in myoblasts compared to myotubes[42,43], which represent more differentiated muscle. The authors postulate that this uptake difference could be due to the processes occurring along the differentiation. Another interesting plasticity phenotype is monocyte to macrophage differentiation and further macrophage polarization. McParland *et al* used PEGylated AuNPs to show a higher

internalization in macrophages compared to monocytes, and a better uptake efficiency when macrophages were M2-type[44]. Taken together, these studies confirm an effect of differentiation in the NP uptake. Of course those processes (differentiation, polarization, EMT...) are accompanied by ECM changes, notably hyaluronan coat of cells[45]. Solier *et al* showed for example than inflammatory M1 macrophages were more prone to metal ions uptake, via the HA-CD44 axis, than primary monocytes[35]. It would be of great interest to perform a global survey of GAG or hyaluronan uptake processes in all those cell types and correlate this with NP internalization.

The higher uptake of nanoparticles in mesenchymal cells is an encouraging feature for nanomedicine approaches. Indeed, in most tumours, mesenchymal cells are the most aggressive, prone to metastasis and radio and chemoresistant. This is confirmed by the study of Brill-Karniely *et al*[46], who showed a correlation between cancer aggressiveness features, such as metastatic capacity, cell uptake of particles, including nanoparticles, and cell deformability. In an elegant study, they also demonstrated that an EMT signature can be attributed to cells with the highest uptake capacity. In contrast, cells from the same cancer line, and selected for not uptaking NPs had a signature specific to epithelial cells. In addition, several teams have successfully demonstrated the ability to identify drug-resistant and aggressive cells by sorting their capacity of NP uptake[47,48]. In another study, Ma *et al* showed that drug-resistant repopulating cells internalize more microparticles than original cells[49]. A 2024 study obtained a similar pattern using a lung carcinoma model, with a more efficient internalization in drug-tolerant persister cells compared to the original cell line[37]. All those research results can be related to the models used in our study. Indeed, the HMLE model, a relevant model for EMT process, harbours a higher NP uptake in mesenchymal cells that are radio- and chemoresistant and have extreme mesenchymal characteristics[17,25].

To conclude, this work shows that an opportunistic entry of metallic NPs via the HA/CD44 axis is present in breast cancer cells, mostly of mesenchymal phenotype. An *in vivo* approach would be necessary to confirm this preferential distribution of metallic NPs towards aggressive and resistant cells in the tumor context but also to determine whether their endocytosis in immune cells could impact radio-therapeutic strategies.

MATERIALS AND METHODS

Cell culture. Twelve breast cancer cell lines were used for this study. All cells were routinely cultured at 37°C in a humidified atmosphere containing 5% CO_2 and checked for the absence of mycoplasma (MycoAlert™ Mycoplasma Detection Kits, Lonza). MDA-MB-231 (ATCC number HTB-26), T47D (ATCC number HTB-133), MDA-MB-157 (ATCC number HTB-24), MDA-MB-436 (ATCC number HTB-130), ZR-75-1 (ATCC number CRL-1500), SKBR3 (ATCC number HTB-30), MCF7 (ATCC number HTB-22) were grown in Dulbecco's Modified Eagle's Medium (DMEM GlutaMAX, Thermo Scientific), supplemented with 10% (v/v) heat-inactivated fetal bovine serum (Thermo Scientific), 1 mM antibiotic-antimycotic (Invitrogen; Thermo Fisher Scientific). SUM159-PT was cultured in Dulbecco's Modified Eagle Medium F12 (DMEM F12 GlutaMAX, Thermo Scientific) supplemented with 5% (v/v) heat-inactivated fetal bovine serum (Thermo Scientific), 1 mM antibiotic-antimycotic (Invitrogen; Thermo Fisher Scientific) and additionally supplemented with 10µg/ml of insulin (I9278-5ML, Sigma-Aldrich) and 0,5µg/ml of hydrocortisone (H4001, Sigma-Aldrich). The R.A. Weinberg lab (Whitehead Institute for Biomedical Research, MIT) generously provided the HMLE cell line[17]. Upon treatment with 10ng/ml of TGFβ1 (580704, Biolegend), HMLE epithelial cells transitioned into mesenchymal cells within a few days. They were cultured in Dulbecco's Modified Eagle Medium F12 (DMEM F12 GlutaMAX, Thermo Scientific) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (Thermo Scientific), 1 mM antibiotic-antimycotic (Invitrogen;Thermo Fisher Scientific) and additionally supplemented with 10µg/ml of insulin (I9278-5ML, Sigma-Aldrich), 10 ng/mL human epidermal growth factor (E9644, Sigma-Aldrich) and 0,5µg/ml of hydrocortisone (H4001, Sigma-Aldrich). The HMLE-M cells were cultured in the same medium, completed with 5ng/ml of TGFβ1 in the culture medium. Similarly, the MCF10A cell line (ATCC number CRL-10317) transitioned into mesenchymal cell upon treatment with 10ng/ml of TGFβ1 within a few days. They were cultured in Dulbecco's Modified Eagle Medium F12 (DMEM F12 GlutaMAX, Thermo Scientific)

supplemented with 5% (v/v) horse serum (11510516, Gibco, Fisher Scientific), 1 mM antibiotic-antimycotic (Invitrogen; Thermo Fisher Scientific) and additionally supplemented with 10µg/ml of insulin (I9278-5ML, Sigma-Aldrich), 20 ng/mL human epidermal growth factor (E9644, Sigma-Aldrich), 0,1µg/ml of Cholera toxin (C8052, Sigma-Aldrich) and 0,5µg/ml of hydrocortisone (H4001, Sigma-Aldrich). Again, the mesenchymal status was maintained with 10ng/ml of TGFβ1 added to the culture medium.

Nanoparticles. Titanium dioxide nanoparticles were obtained from Joint Research Centre Nanomaterials repository (JRC). Suspensions of NM100 and NM103 were prepared according to the Nanogenotox protocol at the European scale. Approximately 15mg of powder was weighed in a scintillation vial of 20ml and pre-wet with 30µl of Ethanol 96°. Suspensions were prepared at a concentration of 2,56 mg/ml in 0,05% BSA before dispersing by ultrasonic probe for 7'54 at 20% amplitude in a 4°C bath. Suspensions were characterized by Dynamic Light Scattering (DLS) measurements using a Nanosizer ZS (Malvern) in back-scattering configuration (173°). AuNP@PEG-NH2 Nanoparticles were synthetized according to Turkevich method at Institut de Chimie Physique (ICP) by Pr. Sicard's team (Gilles et al., 2014). Before any exposure, nanoparticles suspensions are mixed thoroughly and added to the culture medium, not directly in the culture wells to avoid any artefact. Concentrations are expressed as µg/cm², to take into account sedimentation of nanoparticles and therefore avoiding a potential bias due to different volumes of culture media.

Expression modification with lentiviral vectors. Lentiviral vectors were generated at the Genetic engineering and protein biochemistry platform of CEA/IRCM. 293T cells (ATCC CRL-3216) were plated in 175 cm² flasks with a density of 9000 cells per cm^2 and cultured in DMEM (4,5g/L glucose + GlutaMAXTM Supplement+ pyruvate) + 1% penicillin-streptomycin + 10% FCS for 72hours. Cells were co-transfected with packaging plasmids (70µg of pCMV-VSV-G : Addgene #8454 and 100µg of pCMVΔR8.91[50]) and 100µg of expression vector using the calcium phosphate method. The generated DNA precipitate was added to fresh

medium and incubated with previously plated cells. Upon 17 hours of incubation at 37°C with 5% CO2, the medium was changed, and cells cultured for additional 48 hours. Then, the culture medium containing viral particles was filtered on 0,45µm. The filtered suspension was centrifuged at 83000g for 90min at 4°C. Finally, the pellet was suspended in 200µl PBS and frozen at -80°C. Virus titration was performed by exposing 10^5 293T cells to viral particles in 24-well plates. Four serial 5-fold dilutions were tested for each lentivirus, starting with a volume of 0.25µl of frozen initial suspension. After 72hours of culture, cells were washed three times with PBS, harvested by flushing, and the percentage of fluorescent GFP+ cells was further determined by flow cytometry. The viral titer is based on the condition where less than 30% of cells are GFP+, according to the following formula: titer (particles per µl) = (number of plated cells x %age of GFP+ cells)/volume of virus in this condition. The lentiviral pTrip-MND-GFP-H1-shCTRL (HCV) was used as a control vector encoding a shRNA targeting HCV and the pTRIP-MND-GFP-H1-SanD1-sh3_CD44 construct was used to encode shRNA sequences targeting CD44 (generous gift from J Calvo, iRCM, CEA). Transduction lasted for 3 days at 37°C and 5% CO2 in presence of scramble and shRNA-CD44 vectors (MOI = 10). Transduced cells were washed three times using PBS and harvested. After one week of culture, cells were sorted on GFP signal on a FACSAria™.

Hyaluronidase treatment. After 24h of culture, cells were treated with 200U/mL of hyaluronidase (H1115000, Sigma-Aldrich) for 2h, before the exposure to 16µg/cm² of TiO_2 nanoparticles. Cells were collected 24h after exposure to nanoparticles and washed twice in PBS. The SSC deviation signals were measured by flow cytometry, for 10000 cells in each sample. Statistical analysis was performed with GraphPad Prism 9.

Flow cytometry. Cells were harvested from flasks or plates using a 0.05% TrypLE express solution (Fisher Scientific, Illkirch, France).and a 5 minute centrifugation at 300g. After two PBS washes, Cells were counted using an automated cell counter (TC20, Biorad, Marnes la

Coquette, France), with trypan blue exclusion. A total of 200.000 cells were stained with 2µl of each of the following antibodies: CD24-PE (ML5 clone, 562789, BD BioScience), CD44 FITC (555478 BD BioScience) and e-cadhérine APC – CD324 (EXbio) for 15min at 4°C. Cells were washed and centrifuged for 5 min at 300g and pellets were resuspended in PBS-1% BSA. Cells were analysed on a Novocyte instrument (ACEA Biosciences), considering at least 10000 events per sample. Statistical analysis was performed with GraphPad Prism 9.

Darkfield microscopy. Darkfield microscopy was used to visualize gold and TiO_2 nanoparticles inside cells. Cells were plated cells on microscopic slides 24h before exposure to nanoparticles. $Ti0_2$ NPs (NM100 and NM103) were added at a concentration of 6,46µg/cm² and AuNPs- NH2 were added at 14,3µg/cm². After incubation, slides were washed twice and fixed using a 4% paraformaldehyde solution for 15min. After rinsing with PBS, the slides were mounted with ProlonGold anti-fade reagent (11539306, Fisher Scientific.). The slides were analysed under a BX40 Olympus microscope, with a 50X objective.

HAPB detection by confocal microscopy and flow cytometry. For detection with microscopy, cells were seeded on 4-well glass slides (80427, IBIDI). After 72h of culture, cells were washed with PBS and fixed with a 4% paraformaldehyde solution for 15 min. A PBS washing was followed by an incubation with 2% BSA for 1 hour at room temperature. Cells were then incubated with biotinylated Hyaluronic Acid Binding Protein (HABP, ref 385911-50UG, Millipore) at a dilution of 1:250 in a blocking buffer for 1h. The cells were rinsed 3 times with PBS before incubation with Streptavidin-Alexa Fluor™ 488 goat anti-mouse secondary antibody (Invitrogen, ThermoFisher, Illkirch, France), at a dilution of 1:500 in a blocking buffer for 45 min. Cells were rinsed 3 times with washing buffer and stained with 1 µg/mL Hoechst 33342 for 15 min. After a final rinse, slides were mounted with ProlonGold anti-fade reagent (Fisher Scientific, Illkirch, France) and sealed. Stained cells were analysed on a NIKON Ti2 / GATACA, W1 spinning disk microscope with 60X oil immersion objective and images were treated using the Fiji cell-image analysis software.

For HAPB detection by flow cytometry**,** 200000 cells were harvested from culture supports, and were centrifuged for 5 min at 300 g. Pellets were resuspended in PBS-1% BSA with Biotinylated Hyaluronic acid binding protein (385911-50UG, Millipore) at a dilution of 1:125, for 90 min. After that, cells were washed twice and pellets were resuspended in PBS-1% BSA with streptavidin Alexa fluor 488 (JIR016-540-084, Ozyme) at a dilution of 1:1000 for 30min. After another two washes, pellets were resuspended in PBS-1% BSA. Cells were analysed on a Novocyte instrument (Agilent). Statistical analysis was performed with GraphPad Prism 9.

ICP-MS. Cells were seeded in 25 cm^2 flasks and exposed to 32µg/cm^2 of AuNP for 6h and 24 h, or 16µg/cm^2 of TiO_2 NPs for 24h. Cells were washed three times in PBS, before being harvested. Cell counts were performed in triplicate using an automatic cell counter (TC20, Biorad, Marnes la Coquette, France), followed by centrifugation. For gold quantification, cell pellets were digested in a nitric acidsolution, according to the standard procedures of the LNE (Laboratoire National de Métrologie et d'Essais, Paris, France; www.lne.fr). For titanium quantification, cells were digested in hydrofluoric acid and nitric acid, according to LNE's procedures. The total titanium or gold masses were measured using Inductively Coupled Plasma–Mass Spectrometer (ICP–MS) and normalized to the cell number in each sample. Three measures were performed per sample and analysed with GraphPad Prism 9.

Transcriptome Analysis. For both HMLE-E and HMLE-M cells, 100000 cells were plated in 6 wells plates and cultured as described above. After 24h, cells were exposed for 24 or 48 hours to 16µg/cm^2 TiO_2 NM100, TiO_2 NM103, AuNPs-COOH, or AuNPs-NH2 (table 1). Briefly, a 0.05% TrypLE express solution (Fisher Scientific, Illkirch, France) was added to each well and incubated at 37°C until dissociation, followed by a 5 minutes centrifugation at 300g. Cell pellets were then snap-frozen and stored at -80°C.

Total RNA was extracted from frozen HMLE cell pellets with Total RNA purification kit (reference 17240, Norgen Biotek Corp.), according to the manufacturer's instructions. DNAse treatment was performed using TURBO DNA-free kit (Invitrogen; Thermo Fisher Scientific,

Inc.). After validation of the RNA quality with Bioanalyzer 2100 (using Agilent RNA6000 nano chip kit), 100 ng of total RNA were reverse-transcribed following the GeneChip® WT Plus Reagent Kit (Thermofisher). Briefly, the resulting double strand cDNA was used for *in vitro* transcription with T7 RNA polymerase (all these steps are included in the WT cDNA synthesis and amplification kit of Thermofischer). After purification according to Thermofisher protocol, 5.5 µg of Sens Target DNA were fragmented and biotin labelled. After control of fragmentation using Bioanalyzer 2100, cDNA was then hybridized to GeneChip® Clariom S Human (Thermofischer) at 45°C for 17 hours. After overnight hybridization, chips were washed on the fluidic station FS450 following specific protocols (Thermofischer) and scanned using the GCS3000 7G. The scanned images were analyzed with Expression Console software (Thermofischer) to obtain raw data (cel files) and metrics for Quality Controls. Raw data were normalized using the Robust Multichip Algorithm (RMA) in Bioconductor using Brain array EntrezGene CDF version 22 for annotations[51]. Statistics were performed using Partek GS 7.0 ® . Afterwards, gene expression and comparison between samples was analysed thanks to the TAC software (Applied biosystems). ANOVA was used to detect genes with a gene-level fold change >2 or <-2, and with a FDR-corrected p-value <0,05.

Expression analysis by RT-qPCR. Total RNA was extracted from cell pellets with the RNeasy Plus Micro kit (Qiagen) and reverse transcribed with random primers and Superscript IV VILO (Invitrogen), following the manufacturer's recommendations. Quantitative PCR was performed using the iTaq™ Universal Probes Supermix (Bio-Rad) and Taqman probes (Thermofisher). The references of the Taqman probe sets used are as follows : GAPDH : Hs99999905_m1, *CD44v2-10* : Hs01075866_m1, *CD44s* : Hs01081473_m1, *HAS2* : Hs00193435_m1, *HAS3* : Hs00193436_m1. A ΔΔCt method was used for comparative analysis, using GAPDH as a control gene. A RQ calculation was performed as recommended, using appropriate control sample depending on the experiment. Statistical analysis was performed with GraphPad Prism 9.

ASSOCIATED CONTENT

Supporting Information.

Supplementary figures and tables are available.

AUTHOR INFORMATION

Corresponding Author

*Emmanuelle Bourneuf. CEA Fontenay-Aux-Roses. E-mail : emmanuelle.bourneuf@cea.fr

Author Contributions

Performed experiments: MH, CM, NF, CL, GP, JN, EB ; Analysed data : MH, EB ; Wrote the manuscript : CM, MH, EB ; Secured funding and supervised the study : AC, SC, EB. All authors have read and agreed to the published version of the manuscript.

ACKNOWLEDGEMENTS

This work was supported by the Transverse Division n°4 (Radiobiology) of the French Alternative Energies and Atomic Energy Commission (CEA). M. Hullo was a recipient of a PhD fellowship from the French Ministry of Higher Education, Research and Innovation. The authors thank Romain Grall (previously at CEA) for initial contribution to the project. The ICP–MS experiments were conducted on the Platform of the LNE laboratory (Laboratoire National de Métrologie et d'Essais, Paris, France). Creation and production of the lentivirus was performed by the Genetic engineering and protein biochemistry platform of CEA/IRCM (Fontenay-aux-Roses, France). The authors are very grateful to Julien Calvo from CEA who

generously gave access to lentiviral products. We also thank Sébastien Jacques from the GENOMIC' platform of Cochin Institute for the microarray experiments.

REFERENCES

(1) Wu, Y.; Song, Y.; Wang, R.; Wang, T. Molecular Mechanisms of Tumor Resistance to Radiotherapy. *Mol Cancer* **2023**, *22* (1), 96. https://doi.org/10.1186/s12943-023-01801-2.

(2) Vozenin, M.-C.; Bourhis, J.; Durante, M. Towards Clinical Translation of FLASH Radiotherapy. *Nat Rev Clin Oncol* **2022**, *19* (12), 791–803. https://doi.org/10.1038/s41571-022-00697-z.

(3) Tremi, I.; Spyratou, E.; Souli, M.; Efstathopoulos, E. P.; Makropoulou, M.; Georgakilas, A. G.; Sihver, L. Requirements for Designing an Effective Metallic Nanoparticle (NP)-Boosted Radiation Therapy (RT). *Cancers* **2021**, *13* (13), 3185. https://doi.org/10.3390/cancers13133185.

(4) Penninckx, S.; Heuskin, A.-C.; Michiels, C.; Lucas, S. Gold Nanoparticles as a Potent Radiosensitizer: A Transdisciplinary Approach from Physics to Patient. *Cancers* **2020**, *12* (8), 2021. https://doi.org/10.3390/cancers12082021.

(5) Hu, Y.; Paris, S.; Barsoumian, H.; Abana, C. O.; He, K.; Wasley, M.; Younes, A. I.; Masrorpour, F.; Chen, D.; Yang, L.; Dunn, J. D.; Zhang, J.; Gandhi, S.; Nguyen, Q.-N.; Cortez, M. A.; Welsh, J. Radiation Therapy Enhanced by NBTXR3 Nanoparticles Overcomes Anti-PD1 Resistance and Evokes Abscopal Effects. *Int J Radiat Oncol Biol Phys* **2021**, *111* (3), 647–657. https://doi.org/10.1016/j.ijrobp.2021.06.041.

(6) Hainfeld, J. F.; Slatkin, D. N.; Smilowitz, H. M. The Use of Gold Nanoparticles to Enhance Radiotherapy in Mice. *Phys Med Biol* **2004**, *49* (18), N309-315. https://doi.org/10.1088/0031-9155/49/18/n03.

(7) Zhang, Y.; Huang, F.; Ren, C.; Liu, J.; Yang, L.; Chen, S.; Chang, J.; Yang, C.; Wang, W.; Zhang, C.; Liu, Q.; Liang, X.-J.; Liu, J. Enhanced Radiosensitization by Gold Nanoparticles with Acid-Triggered Aggregation in Cancer Radiotherapy. *Adv Sci (Weinh)* **2019**, *6* (8), 1801806. https://doi.org/10.1002/advs.201801806.

(8) Nosrati, H.; Salehiabar, M.; Charmi, J.; Yaray, K.; Ghaffarlou, M.; Balcioglu, E.; Ertas, Y. N. Enhanced In Vivo Radiotherapy of Breast Cancer Using Gadolinium Oxide and Gold Hybrid Nanoparticles. *ACS Appl Bio Mater* **2023**, *6* (2), 784–792. https://doi.org/10.1021/acsabm.2c00965.

(9) Lawrence, P. T.; Daniels, A. S.; Tierney, A. J.; Sykes, E. C. H.; Mace, C. R. Ligand Shell Thickness of PEGylated Gold Nanoparticles Controls Cellular Uptake and Radiation Enhancement. *ACS Omega* **2024**, *9* (34), 36847–36856. https://doi.org/10.1021/acsomega.4c06568.

(10) Rennick, J. J.; Johnston, A. P. R.; Parton, R. G. Key Principles and Methods for Studying the Endocytosis of Biological and Nanoparticle Therapeutics. *Nat Nanotechnol* **2021**, *16* (3), 266–276. https://doi.org/10.1038/s41565-021-00858-8.

(11) Sousa de Almeida, M.; Susnik, E.; Drasler, B.; Taladriz-Blanco, P.; Petri-Fink, A.; Rothen-Rutishauser, B. Understanding Nanoparticle Endocytosis to Improve Targeting Strategies in Nanomedicine. *Chem. Soc. Rev.* **2021**, 10.1039.D0CS01127D. https://doi.org/10.1039/D0CS01127D.

(12) Dongre, A.; Weinberg, R. A. New Insights into the Mechanisms of Epithelial-Mesenchymal Transition and Implications for Cancer. *Nat. Rev. Mol. Cell Biol.* **2019**, *20* (2), 69–84. https://doi.org/10.1038/s41580-018-0080-4.
(13) Saxena, K.; Jolly, M. K.; Balamurugan, K. Hypoxia, Partial EMT and Collective Migration: Emerging Culprits in Metastasis. *Transl Oncol* **2020**, *13* (11), 100845. https://doi.org/10.1016/j.tranon.2020.100845.
(14) Collins, A. R.; Annangi, B.; Rubio, L.; Marcos, R.; Dorn, M.; Merker, C.; Estrela-Lopis, I.; Cimpan, M. R.; Ibrahim, M.; Cimpan, E.; Ostermann, M.; Sauter, A.; Yamani, N. E.; Shaposhnikov, S.; Chevillard, S.; Paget, V.; Grall, R.; Delic, J.; de-Cerio, F. G.; Suarez-Merino, B.; Fessard, V.; Hogeveen, K. N.; Fjellsbø, L. M.; Pran, E. R.; Brzicova, T.; Topinka, J.; Silva, M. J.; Leite, P. E.; Ribeiro, A. R.; Granjeiro, J. M.; Grafström, R.; Prina-Mello, A.; Dusinska, M. High Throughput Toxicity Screening and Intracellular Detection of Nanomaterials. *WIREs Nanomed Nanobiotechnol* **2017**, *9* (1). https://doi.org/10.1002/wnan.1413.
(15) Zucker, R. M.; Massaro, E. J.; Sanders, K. M.; Degn, L. L.; Boyes, W. K. Detection of TiO2 Nanoparticles in Cells by Flow Cytometry. *Cytometry* **2010**, *77A* (7), 677–685. https://doi.org/10.1002/cyto.a.20927.
(16) Hullo, M.; Grall, R.; Perrot, Y.; Mathé, C.; Ménard, V.; Yang, X.; Lacombe, S.; Porcel, E.; Villagrasa, C.; Chevillard, S.; Bourneuf, E. Radiation Enhancer Effect of Platinum Nanoparticles in Breast Cancer Cell Lines: In Vitro and In Silico Analyses. *Int J Mol Sci* **2021**, *22* (9), 4436. https://doi.org/10.3390/ijms22094436.
(17) Mani, S. A.; Guo, W.; Liao, M.-J.; Eaton, E. N.; Ayyanan, A.; Zhou, A. Y.; Brooks, M.; Reinhard, F.; Zhang, C. C.; Shipitsin, M.; Campbell, L. L.; Polyak, K.; Brisken, C.; Yang, J.; Weinberg, R. A. The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells. *Cell* **2008**, *133* (4), 704–715. https://doi.org/10.1016/j.cell.2008.03.027.
(18) Wendt, M. K.; Schiemann, W. P. Therapeutic Targeting of the Focal Adhesion Complex Prevents Oncogenic TGF-Beta Signaling and Metastasis. *Breast Cancer Res* **2009**, *11* (5), R68. https://doi.org/10.1186/bcr2360.
(19) Yang, J.; Antin, P.; Berx, G.; Blanpain, C.; Brabletz, T.; Bronner, M.; Campbell, K.; Cano, A.; Casanova, J.; Christofori, G.; Dedhar, S.; Derynck, R.; Ford, H. L.; Fuxe, J.; García de Herreros, A.; Goodall, G. J.; Hadjantonakis, A.-K.; Huang, R. Y. J.; Kalcheim, C.; Kalluri, R.; Kang, Y.; Khew-Goodall, Y.; Levine, H.; Liu, J.; Longmore, G. D.; Mani, S. A.; Massagué, J.; Mayor, R.; McClay, D.; Mostov, K. E.; Newgreen, D. F.; Nieto, M. A.; Puisieux, A.; Runyan, R.; Savagner, P.; Stanger, B.; Stemmler, M. P.; Takahashi, Y.; Takeichi, M.; Theveneau, E.; Thiery, J. P.; Thompson, E. W.; Weinberg, R. A.; Williams, E. D.; Xing, J.; Zhou, B. P.; Sheng, G.; EMT International Association (TEMTIA). Guidelines and Definitions for Research on Epithelial-Mesenchymal Transition. *Nat Rev Mol Cell Biol* **2020**, *21* (6), 341–352. https://doi.org/10.1038/s41580-020-0237-9.
(20) Li, S.-J.; Wei, X.-H.; Zhan, X.-M.; He, J.-Y.; Zeng, Y.-Q.; Tian, X.-M.; Yuan, S.-T.; Sun, L. Adipocyte-Derived Leptin Promotes PAI-1 -Mediated Breast Cancer Metastasis in a STAT3/MiR-34a Dependent Manner. *Cancers (Basel)* **2020**, *12* (12), 3864. https://doi.org/10.3390/cancers12123864.
(21) Onder, T. T.; Gupta, P. B.; Mani, S. A.; Yang, J.; Lander, E. S.; Weinberg, R. A. Loss of E-Cadherin Promotes Metastasis via Multiple Downstream Transcriptional Pathways. *Cancer Res* **2008**, *68* (10), 3645–3654. https://doi.org/10.1158/0008-5472.CAN-07-2938.
(22) Charafe-Jauffret, E.; Ginestier, C.; Monville, F.; Finetti, P.; Adélaïde, J.; Cervera, N.; Fekairi, S.; Xerri, L.; Jacquemier, J.; Birnbaum, D.; Bertucci, F. Gene Expression Profiling of Breast Cell Lines Identifies Potential New Basal Markers. *Oncogene* **2006**, *25* (15), 2273–2284. https://doi.org/10.1038/sj.onc.1209254.
(23) Boquest, A. C.; Shahdadfar, A.; Frønsdal, K.; Sigurjonsson, O.; Tunheim, S. H.; Collas, P.; Brinchmann, J. E. Isolation and Transcription Profiling of Purified Uncultured Human

Stromal Stem Cells: Alteration of Gene Expression after In Vitro Cell Culture. *MBoC* **2005**, *16* (3), 1131–1141. https://doi.org/10.1091/mbc.e04-10-0949.
(24) Lim, E.; Wu, D.; Pal, B.; Bouras, T.; Asselin-Labat, M.-L.; Vaillant, F.; Yagita, H.; Lindeman, G. J.; Smyth, G. K.; Visvader, J. E. Transcriptome Analyses of Mouse and Human Mammary Cell Subpopulations Reveal Multiple Conserved Genes and Pathways. *Breast Cancer Res* **2010**, *12* (2), R21. https://doi.org/10.1186/bcr2560.
(25) Bontemps, I.; Lallemand, C.; Biard, D.; Dechamps, N.; Kortulewski, T.; Bourneuf, E.; Siberchicot, C.; Boussin, F.; Chevillard, S.; Campalans, A.; Lebeau, J. Loss of CD24 Promotes Radiation- and Chemo-resistance by Inducing Stemness Properties Associated with a Hybrid E/M State in Breast Cancer Cells. *Oncol Rep* **2023**, *49* (1), 4. https://doi.org/10.3892/or.2022.8441.
(26) Olsson, E.; Honeth, G.; Bendahl, P.-O.; Saal, L. H.; Gruvberger-Saal, S.; Ringnér, M.; Vallon-Christersson, J.; Jönsson, G.; Holm, K.; Lövgren, K.; Fernö, M.; Grabau, D.; Borg, Å.; Hegardt, C. CD44 Isoforms Are Heterogeneously Expressed in Breast Cancer and Correlate with Tumor Subtypes and Cancer Stem Cell Markers. *BMC Cancer* **2011**, *11* (1), 418. https://doi.org/10.1186/1471-2407-11-418.
(27) Passi, A.; Vigetti, D.; Buraschi, S.; Iozzo, R. V. Dissecting the Role of Hyaluronan Synthases in the Tumor Microenvironment. *FEBS J* **2019**, *286* (15), 2937–2949. https://doi.org/10.1111/febs.14847.
(28) Porsch, H.; Bernert, B.; Mehić, M.; Theocharis, A. D.; Heldin, C.-H.; Heldin, P. Efficient TGFβ-Induced Epithelial–Mesenchymal Transition Depends on Hyaluronan Synthase HAS2. *Oncogene* **2013**, *32* (37), 4355–4365. https://doi.org/10.1038/onc.2012.475.
(29) Willmann, W.; Dringen, R. How to Study the Uptake and Toxicity of Nanoparticles in Cultured Brain Cells: The Dos and Don't Forgets. *Neurochem Res* **2019**, *44* (6), 1330–1345. https://doi.org/10.1007/s11064-018-2598-4.
(30) Johnston, S. T.; Faria, M.; Crampin, E. J. Isolating the Sources of Heterogeneity in Nano-Engineered Particle-Cell Interactions. *J R Soc Interface* **2020**, *17* (166), 20200221. https://doi.org/10.1098/rsif.2020.0221.
(31) Liu, X.; Ghosh, D. Intracellular Nanoparticle Delivery by Oncogenic KRAS-Mediated Macropinocytosis. *Int J Nanomedicine* **2019**, *14*, 6589–6600. https://doi.org/10.2147/IJN.S212861.
(32) Griffiths, G.; Gruenberg, J.; Marsh, M.; Wohlmann, J.; Jones, A. T.; Parton, R. G. Nanoparticle Entry into Cells; the Cell Biology Weak Link. *Advanced Drug Delivery Reviews* **2022**, *188*, 114403. https://doi.org/10.1016/j.addr.2022.114403.
(33) Francia, V.; Yang, K.; Deville, S.; Reker-Smit, C.; Nelissen, I.; Salvati, A. Corona Composition Can Affect the Mechanisms Cells Use to Internalize Nanoparticles. *ACS Nano* **2019**, *13* (10), 11107–11121. https://doi.org/10.1021/acsnano.9b03824.
(34) Montizaan, D.; Bartucci, R.; Reker-Smit, C.; de Weerd, S.; Åberg, C.; Guryev, V.; Spierings, D. C. J.; Salvati, A. Genome-Wide Forward Genetic Screening to Identify Receptors and Proteins Mediating Nanoparticle Uptake and Intracellular Processing. *Nat Nanotechnol* **2024**, *19* (7), 1022–1031. https://doi.org/10.1038/s41565-024-01629-x.
(35) Solier, S.; Müller, S.; Cañeque, T.; Versini, A.; Mansart, A.; Sindikubwabo, F.; Baron, L.; Emam, L.; Gestraud, P.; Pantoş, G. D.; Gandon, V.; Gaillet, C.; Wu, T.-D.; Dingli, F.; Loew, D.; Baulande, S.; Durand, S.; Sencio, V.; Robil, C.; Trottein, F.; Péricat, D.; Näser, E.; Cougoule, C.; Meunier, E.; Bègue, A.-L.; Salmon, H.; Manel, N.; Puisieux, A.; Watson, S.; Dawson, M. A.; Servant, N.; Kroemer, G.; Annane, D.; Rodriguez, R. A Druggable Copper-Signalling Pathway That Drives Inflammation. *Nature* **2023**, *617* (7960), 386–394. https://doi.org/10.1038/s41586-023-06017-4.
(36) Müller, S.; Sindikubwabo, F.; Cañeque, T.; Lafon, A.; Versini, A.; Lombard, B.; Loew, D.; Wu, T.-D.; Ginestier, C.; Charafe-Jauffret, E.; Durand, A.; Vallot, C.; Baulande, S.; Servant, N.; Rodriguez, R. CD44 Regulates Epigenetic Plasticity by Mediating Iron

Endocytosis. *Nat. Chem.* **2020**, *12* (10), 929–938. https://doi.org/10.1038/s41557-020-0513-5.

(37) Tsai, T.; Wu, S.; Lai, Y.; Wang, H.; Hou, P.; Huang, Y.; Chen, H. H.; Su, W. CD44-Hyaluronan Mediating Endocytosis of Iron-Platinum Alloy Nanoparticles Induces Ferroptotic Cell Death in Mesenchymal-State Lung Cancer Cells with Tyrosine Kinase Inhibitor Resistance. *Acta Biomater* **2024**, *186*, 396–410. https://doi.org/10.1016/j.actbio.2024.07.020.

(38) Udabage, L.; Brownlee, G. R.; Nilsson, S. K.; Brown, T. J. The Over-Expression of HAS2, Hyal-2 and CD44 Is Implicated in the Invasiveness of Breast Cancer. *Exp Cell Res* **2005**, *310* (1), 205–217. https://doi.org/10.1016/j.yexcr.2005.07.026.

(39) Ngo, W.; Wu, J. L. Y.; Lin, Z. P.; Zhang, Y.; Bussin, B.; Granda Farias, A.; Syed, A. M.; Chan, K.; Habsid, A.; Moffat, J.; Chan, W. C. W. Identifying Cell Receptors for the Nanoparticle Protein Corona Using Genome Screens. *Nat Chem Biol* **2022**, *18* (9), 1023–1031. https://doi.org/10.1038/s41589-022-01093-5.

(40) Boehnke, N.; Straehla, J. P.; Safford, H. C.; Kocak, M.; Rees, M. G.; Ronan, M.; Rosenberg, D.; Adelmann, C. H.; Chivukula, R. R.; Nabar, N.; Berger, A. G.; Lamson, N. G.; Cheah, J. H.; Li, H.; Roth, J. A.; Koehler, A. N.; Hammond, P. T. Massively Parallel Pooled Screening Reveals Genomic Determinants of Nanoparticle Delivery. *Science* **2022**, *377* (6604), eabm5551. https://doi.org/10.1126/science.abm5551.

(41) Pannico, M.; Calarco, A.; Peluso, G.; Musto, P. Functionalized Gold Nanoparticles as Biosensors for Monitoring Cellular Uptake and Localization in Normal and Tumor Prostatic Cells. *Biosensors* **2018**, *8* (4), 87. https://doi.org/10.3390/bios8040087.

(42) Guglielmi, V.; Carton, F.; Vattemi, G.; Arpicco, S.; Stella, B.; Berlier, G.; Marengo, A.; Boschi, F.; Malatesta, M. Uptake and Intracellular Distribution of Different Types of Nanoparticles in Primary Human Myoblasts and Myotubes. *Int J Pharm* **2019**, *560*, 347–356. https://doi.org/10.1016/j.ijpharm.2019.02.017.

(43) Costanzo, M.; Vurro, F.; Cisterna, B.; Boschi, F.; Marengo, A.; Montanari, E.; Meo, C. D.; Matricardi, P.; Berlier, G.; Stella, B.; Arpicco, S.; Malatesta, M. Uptake and Intracellular Fate of Biocompatible Nanocarriers in Cycling and Noncycling Cells. *Nanomedicine* **2019**, *14* (3), 301–316. https://doi.org/10.2217/nnm-2018-0148.

(44) MacParland, S. A.; Tsoi, K. M.; Ouyang, B.; Ma, X.-Z.; Manuel, J.; Fawaz, A.; Ostrowski, M. A.; Alman, B. A.; Zilman, A.; Chan, W. C. W.; McGilvray, I. D. Phenotype Determines Nanoparticle Uptake by Human Macrophages from Liver and Blood. *ACS Nano* **2017**, *11* (3), 2428–2443. https://doi.org/10.1021/acsnano.6b06245.

(45) Leng, Y.; Abdullah, A.; Wendt, M. K.; Calve, S. Hyaluronic Acid, CD44 and RHAMM Regulate Myoblast Behavior during Embryogenesis. *Matrix Biol* **2019**, *78–79*, 236–254. https://doi.org/10.1016/j.matbio.2018.08.008.

(46) Brill-Karniely, Y.; Dror, D.; Duanis-Assaf, T.; Goldstein, Y.; Schwob, O.; Millo, T.; Orehov, N.; Stern, T.; Jaber, M.; Loyfer, N.; Vosk-Artzi, M.; Benyamini, H.; Bielenberg, D.; Kaplan, T.; Buganim, Y.; Reches, M.; Benny, O. Triangular Correlation (TrC) between Cancer Aggressiveness, Cell Uptake Capability, and Cell Deformability. *Sci. Adv.* **2020**, *6* (3), eaax2861. https://doi.org/10.1126/sciadv.aax2861.

(47) Liu, L.; Zhang, Q.; Wang, C.; Guo, H.; Mukwaya, V.; Chen, R.; Xu, Y.; Wei, X.; Chen, X.; Zhang, S.; Zhou, M.; Dou, H. Single-Cell Diagnosis of Cancer Drug Resistance through the Differential Endocytosis of Nanoparticles between Drug-Resistant and Drug-Sensitive Cancer Cells. *ACS Nano* **2023**, *17* (19), 19372–19386. https://doi.org/10.1021/acsnano.3c07030.

(48) Goldstein, Y.; Cohen, O. T.; Wald, O.; Bavli, D.; Kaplan, T.; Benny, O. Particle Uptake in Cancer Cells Can Predict Malignancy and Drug Resistance Using Machine Learning. *Sci Adv* **2024**, *10* (22), eadj4370. https://doi.org/10.1126/sciadv.adj4370.

(49) Ma, J.; Zhang, Y.; Tang, K.; Zhang, H.; Yin, X.; Li, Y.; Xu, P.; Sun, Y.; Ma, R.; Ji, T.; Chen, J.; Zhang, S.; Zhang, T.; Luo, S.; Jin, Y.; Luo, X.; Li, C.; Gong, H.; Long, Z.; Lu, J.;

Hu, Z.; Cao, X.; Wang, N.; Yang, X.; Huang, B. Reversing Drug Resistance of Soft Tumor-Repopulating Cells by Tumor Cell-Derived Chemotherapeutic Microparticles. *Cell Res* **2016**, *26* (6), 713–727. https://doi.org/10.1038/cr.2016.53.

(50) Zufferey, R.; Nagy, D.; Mandel, R. J.; Naldini, L.; Trono, D. Multiply Attenuated Lentiviral Vector Achieves Efficient Gene Delivery in Vivo. *Nat Biotechnol* **1997**, *15* (9), 871–875. https://doi.org/10.1038/nbt0997-871.

(51) Bolstad, B. M.; Irizarry, R. A.; Astrand, M.; Speed, T. P. A Comparison of Normalization Methods for High Density Oligonucleotide Array Data Based on Variance and Bias. *Bioinformatics* **2003**, *19* (2), 185–193.

Figures for Hullo et al.



Figure 1: Uptake of metallic nanoparticles by T47D and MDA-MB-231 cells.

A. Flow cytometry phenotyping of the epithelial (T47D) and the mesenchymal cell lines (MDA-MB-231). Cells were stained with CD44-FITC, CD24-PE and E-cadherin-APC antibodies. The graph represents the mean of data from 10000 cells. The right panels show phase-contrast images of cell lines T47D and MDA-MB-231, scale corresponds to 100µm. Scale corresponds to 300µm. **B.** Darkfield microscopy images of AuNPs (32nm) internalized in epithelial (T47D) and mesenchymal cells (MDA-MB-231), following a 72h exposure at 14,3 µg/cm^2. Scale corresponds to 10µm. **C.** ICP-MS measure of cytoplasmic gold mass after 6h and 24h exposure with 32 µg/cm2 AuNPs-PEG NH2 (32nm), in T47D and MDA-MB-231 cells. **D.** SSC-A deviation signals from T47D and MDA-MB-231 cells exposed to NM100 TiO_2 NPs with different concentrations (µg/cm²). Cells were exposed for 24h, and suspensions were subjected to flow cytometry analysis. The graph represents the mean of data from 10000 cells, analysed in duplicates. Errors bars are SDs. The statistical significance was determined by using the 2-way Anova test. Note: ns, non-significant; *** $p < 0.0005$ and **** $p < 0.0001$.



Figure 2 : Uptake of TiO_2 nanoparticles in two breast cancer cell models of Epithelial-to-mesenchymal transition.

A. Models of induced epithelial to mesenchymal transition *in vitro* with TGFβ. All cell lines were phenotyped by flow cytometry with CD24-PE, CD44-FITC, and E-cadherin-APC antibodies. The right panels show contrast-phase images of the 4 cell lines, magnification x10. Scale bar 100 µm. **B.** SSC-A deviation signals from HMLE-E and M cells exposed to NM100 TiO_2 NPs with different concentrations (µg/cm²). Cells were exposed for 24h, and suspensions were subjected to flow cytometry analysis. The graph represents the mean of data from 10000 cells, and in duplicates, error bars are SDs. **C.** SSC-A deviation signals from MCF10A-E and M cells exposed to NM100 and NM103 TiO_2 NPs with 16µg/cm². Cells were exposed for 24h, and suspensions were subjected to flow cytometry analysis. The graph represents the mean of data from 10000 cells, and in duplicates, error bars are SDs. The statistical significance was determined by using the 2 way Anova test. Note: ns, non-significant; *** $p < 0.0005$ and **** $p < 0.0001$.



Figure 3 : Gene Set Enrichment Analysis of nanoparticle uptake by HMLE-E and HMLE-M cells.

A. Enrichment plots after analysis comparing the transcriptome dataset with the Chemical and Genetic Perturbations database, grouping signatures retrieved from published studies. The plots from the upper panel present signatures upregulated in HMLE-epithelial cells, whereas the lower panel presents genesets enriched in HMLE mesenchymal cells. **B.** Enrichment plots after analysis comparing the transcriptome dataset with the Gene Ontology database, Cell Component category. In HMLE mesenchymal cells, « Extracellular Matrix » and « Collagen-containing Extracellular Matrix » are the most enriched categories.



Figure 4 : Expression levels of CD44 isoforms in different cell lines affect NP uptake

A and B. CD44s isoform (A) and CD44v2-10 isoform (B) expression in 4 different breast cancer cell lines measured by qRT-PCR. Relative quantification was calculated with T47D (A) or HMLE-M (B) samples as reference samples. Measures of expression were performed in triplicates, and error bars represent RQ min and RQ max values. The statistical significance was determined by using the one-way Anova test, with a Sidak's multiple comparison test. Note: ns, non-significant; * $p < 0.05$ and **** $p < 0.0001$. **C.** Quantification of CD44s and CD44v2-10 expression in HMLE-M and MDA-MB231 cells after expression of shRNAs targeting all isoforms of CD44. Cells were transduced with lentiviral particles encoding anti-CD44 shRNAs and cultured for 9 days before RNA extraction. Relative quantification was calculated with untreated HMLE-M cells as a reference sample. Measures of expression were performed in triplicates, and error bars represent RQ min and RQ max values. The statistical

significance was determined by using the one-way Anova test, with a Dunnett's multiple comparison test. Note: ns, non-significant; *** $p < 0.0005$ and **** $p < 0.0001$. **D.** SSC-A deviation signals from MDA-MB231 cells expressing scramble or anti-CD44 shRNAs, unexposed to NPs (left panel), exposed to NM100 TiO_2 NPs (middle panel) or to NM103 TiO_2 NPs (right panel). The cells were exposed for 24h to a NP concentration of 16µg/cm², and suspensions were subjected to flow cytometry analysis. The graph represents the mean of data from 10000 cells, in duplicates. Statistical significance is validated by Ordinary One-way ANOVA. Ns=non significant, *indicates a p-value<0,05, **indicates a p-value<0,01 and ***indicates a p-value<0,001.



Figure 5 : HAS2 expression, and effect of HA coat modulation on NP uptake

A. HAS2 expression in 4 different breast cancer cell lines measured by qRT-PCR. Relative quantification was calculated with HMLE-E sample as a reference. Measures of expression were performed in triplicates, and error bars represent RQ min and RQ max values. **B.** HAS3 expression in 4 different breast cancer cell lines, measured by qRT-PCR. Relative quantification

was calculated with HMLE-M sample as a reference. Measures of expression were performed in triplicates, and error bars represent RQ min and RQ max values. For A and B, **t**he statistical significance was determined by using the one-way Anova test, with a Sidak's multiple comparison test. Note: ns, non-significant; * $p < 0.05$, ** $p < 0.005$ and **** $p < 0.0001$. **C.** Representative images of hyaluronic acid staining in the 4 different cell lines. Nuclei were stained with Hoescht (blue) and HA Binding proteins coupled to biotin were further detected using streptavidin-FITC (green). Images were obtained by confocal microscopy. Scale bar is 10µm. **D.** Mean Fluorescence Intensity of HABP from at least 10000 cells for each of the 4 indicated cell lines, analysed by flow cytometry. Analysis was performed in triplicates. **E.** SSC-A deviation signals from T47D and MDA-MB231 cells treated with hyaluronidase and exposed to NM100 or NM103 TiO2 NPs. The graph represents the mean of data from 10000 cells, and in duplicates. The statistical analysis comparing untreated vs treated cells was performed with one-way anova. Ns=non significant, *indicates a p-value<0,05 and **indicates a p-value<0,01.

A



B



Figure 6 : CD44s RNA and protein expression in a panel of breast cancer cell lines. **A.** CD44s expression measured by qRT-PCR in breast epithelial (T47D, SKBR3, ZR75-1, MCF7, HMLE-E, MCF10A-E, blue) and mesenchymal cell lines (MDA-MB-231, MDA-MB-436, MDA-MB-157, SUM159PT, HMLE-M, MCF10A-M, red). Measures of expression were performed in triplicates, and error bars represent RQ min and RQ max values. **B.** CD24/CD44 and e-cadherin phenotyping was performed by flow cytometry in epithelial and mesenchymal cells lines. The graph represents the mean of data from 10000 cells. The right panels show contrast-phase images of the 6 cell lines, scale bar 100µm.



Figure 7 : HAS2 RNA expression and HABP immunodetection in a panel of breast cancer cell lines.

A. HAS2 expression measured by qRT-PCR in breast epithelial (T47D, SKBR3, ZR78-1, MCF7, HMLE-E, MCF10A-E) and mesenchymal cell lines (M231, M436, M157, SUM159PT, HMLE-M, MCF10A-M). Measures of expression were performed in triplicates and error bars represent RQ min and RQ max values. **B.** Mean Fluorescence Intensity of HABP-FITC in a mean of 10000 cells from each of the 8 cell lines, analysed by flow cytometry. Analysis was performed in triplicates. **C.** Representative images of hyaluronic acid staining in the 8 different cell lines. Nuclei were stained with Hoescht (blue) and HA Binding proteins coupled to biotin were detected with streptavidin-FITC (green). Images were obtained by confocal microscopy. Scale is 10µm.



Figure 8 : Nanoparticle uptake in breast cancer cell lines, according to the cell phenotype **A.** SSC-A deviation of epithelial (blue) and mesenchymal (red) cell lines, after a 24h exposure to NM100 TiO2 NPs at a concentration of 16µg/cm². Each dot represents the mean deviation obtained with 10000 cells from each cell line. Statistical significance was evaluated with a Mann-Whitney test, *** indicates a p-value<0,001. **B.** SSC-A deviation of epithelial (blue) and mesenchymal (red) cell lines, after a 24h exposure to NM103 TiO2 NPs at a concentration of 16µg/cm². Each dot represents the mean deviation obtained with 10000 cells from each specific cell line. Statistical significance validated by a Mann-Whitney test, *** indicates a p-value<0,001. **C.** ICP-MS quantification of cytoplasmic titanium oxyde mass after a 24h exposure with 16 µg/cm2 of NM100 or NM103 NPs, in 6 epithelial cell lines (T47D, MCF-7, HMLE.E, SKBR3, ZR75.1, MCF10A.E; blue) and 6 mesenchymal cells lines (MDA-MB-231, MDA-MB-157, HMLE.M, MDA-MB-436, SUM159PT, MCF10A.M; red). **D.** ICP-MS quantification of cytoplasmic gold mass after a 24h exposure with 32 µg/cm2 AuNPs-PEG NH2 (32nm), in 4 epithelial cell lines (T47D, MCF-7, HMLE.E, SKBR3; blue) and 4 mesenchymal cells lines (MDA-MB-231, MDA-MB-157, HMLE.M, MDA-MB-436; red). For C and D, **t**he statistical significance was determined by with a Mann-Whitney test. Note: * $p < 0.05$ and ** $p < 0.005$.

Tables for Hullo et al.

Table 1 : Physico chemical features of the four different nanoparticles suspensions used in the transcriptome study.

Nanoparticle Composition	Size (nm)	Z-average (nm)	Charge (mV)	Surface
AuNP	32	35		
AuNP-COOH	32	35	-50	PEG-COOH
TiO2 – NM100	110	225	-25	
TiO2 – NM103	25	170	+5	

Table 2 : List of the most significantly overexpressed genes in Mesenchymal cells compared to epithelial cells

Public Gene IDs	Gene Name	Description	Fold Change	P-val	FDR P-val
NM_006329	FBLN5	fibulin 5	1068,81	5,62E-14	7,09E-11
NM_001135934	POSTN	periostin, osteoblast specific factor	559,85	2,17E-14	4,65E-11
NM_001191322	GREM1	gremlin 1, DAN family BMP antagonist	169,44	1,05E-13	1,11E-10
NM_001142474	NREP	neuronal regeneration related protein	105,59	2,50E-12	1,62E-09
NM_005909	MAP1B	microtubule associated protein 1B	67,82	2,73E-14	5,32E-11
NM_000602	SERPINE1	serpin peptidase inhibitor, clade E, member 1	64,57	5,72E-13	4,72E-10
NM_001128128	ZEB1	zinc finger E-box binding homeobox 1	57,4	1,34E-13	1,31E-10
NM_001311160	THY1	Thy-1 cell surface antigen	48,57	1,59E-12	1,06E-09
NM_001552	IGFBP4	insulin like growth factor binding protein 4	35,9	1,34E-14	4,10E-11
NM_001159	AOX1	aldehyde oxidase 1	33,26	5,20E-12	3,02E-09
NM_001167738	NAV1	neuron navigator 1	28,77	6,24E-12	3,48E-09
NM_014391	ANKRD1	ankyrin repeat domain 1 (cardiac muscle)	28,67	1,35E-12	9,62E-10
NM_003713	PLPP3	phospholipid phosphatase 3	25,03	2,80E-11	1,17E-08
NM_001243286	PVRL3	poliovirus receptor-related 3	24,75	1,93E-14	4,59E-11
NM_001311175	TNFAIP8L3	tumor necrosis factor, alpha-induced protein 8-like 3	22,8	6,65E-12	3,48E-09
NM_001290263	DOCK10	dedicator of cytokinesis 10	16,73	2,57E-11	1,10E-08
NM_005328	HAS2	hyaluronan synthase 2	16,5	6,63E-12	3,48E-09
NM_001134999	FERMT2	fermitin family member 2	7,37	9,51E-14	1,07E-10
NM_014729	TOX	thymocyte selection-associated high mobility group box	6,39	7,25E-12	3,63E-09
NM_004305	BIN1	bridging integrator 1	4,09	1,41E-12	9,79E-10

Table 3 : List of the most significantly overexpressed genes in Epithelial cells compared to mesenchymal cells

Public Gene IDs	Gene Name	Description	Fold Change	P-val	FDR P-val
NM_052886	MAL2	mal, T-cell differentiation protein 2 (gene/pseudogene)	2375,39	3,70E-18	3,97E-14
NM_002354	EPCAM	epithelial cell adhesion molecule	1609,15	5,06E-19	1,09E-14
NM_001034915	ESRP1	epithelial splicing regulatory protein 1	1162,17	6,79E-16	3,64E-12
NM_001077491	KLK5	kallikrein related peptidase 5	584,71	2,62E-13	2,36E-10
NM_000494	COL17A1; MIR936	collagen, type XVII, alpha 1; microRNA 936	180,31	4,37E-14	6,25E-11
NM_001012964	KLK6	kallikrein related peptidase 6	175,08	9,66E-12	4,71E-09
NM_021978	ST14	suppression of tumorigenicity 14 (colon carcinoma)	150,73	5,74E-15	2,05E-11
NM_004360	CDH1	cadherin 1, type 1	90,84	3,62E-14	5,54E-11
NM_001300887	AP1M2	adaptor-related protein complex 1, mu 2 subunit	68,77	1,71E-14	4,59E-11
NM_020672	S100A14	S100 calcium binding protein A14	67,63	8,18E-13	6,50E-10
NM_001260489	LSR	lipolysis stimulated lipoprotein receptor	65,26	1,09E-13	1,11E-10
NM_016267	VGLL1	vestigial-like family member 1	61,44	5,20E-14	6,97E-11
NM_001793	CDH3	cadherin 3, type 1, P-cadherin (placental)	46,15	3,30E-12	1,97E-09
NM_001010872	FAM83B	family with sequence similarity 83, member B	44,22	3,04E-14	5,40E-11
NM_001104548	MIR205HG; MIR205	MIR205 host gene; microRNA 205	41,9	7,06E-14	8,41E-11
NM_005213	CSTA	cystatin A (stefin A)	35,73	1,36E-11	6,19E-09
NM_001114978	TP63	tumor protein p63	33,42	1,22E-11	5,67E-09
NM_003222	TFAP2C	transcription factor AP-2 gamma	28,75	2,70E-12	1,70E-09
NM_174911	FAM84B	family with sequence similarity 84, member B	26,08	2,64E-13	2,36E-10
NM_001171195	ELAVL2	ELAV like neuron-specific RNA binding protein 2	24,27	2,84E-11	1,17E-08
NM_005555	KRT6B	keratin 6B, type II	22,52	7,27E-12	3,63E-09
NM_001003407	ABLIM1	actin binding LIM protein 1	22,37	1,33E-12	9,62E-10
NM_004482	GALNT3	polypeptide N-acetylgalactosaminyltransferase 3	20,14	3,31E-13	2,84E-10
NM_001284406	TMEM40	transmembrane protein 40	17,94	2,38E-11	1,04E-08
NM_001025252	TPD52	tumor protein D52	15,2	6,55E-12	3,48E-09
NM_030949	PPP1R14C	protein phosphatase 1, regulatory (inhibitor) subunit 14C	12,83	1,11E-12	8,49E-10
NM_001017970	TMEM30B	transmembrane protein 30B	11,99	1,83E-11	8,17E-09
NM_001100812	CXCL16	chemokine (C-X-C motif) ligand 16	11,1	2,89E-12	1,77E-09
NM_001127213	LY6E	lymphocyte antigen 6 complex, locus E	9,62	3,27E-14	5,40E-11
NM_003105	SORL1	sortilin-related receptor, L(DLR class) A repeats containing	7,79	1,10E-11	5,25E-09

Table 4 : Hallmarks enriched in epithelial and mesenchymal cells. Hallmarks that are mentionned all present a FDR-corrected q-value <0.05

HALLMARKS	SIZE	ES	NES	FDR q-val
Upregulated in Epithelial cells				
ESTROGEN_RESPONSE_LATE	32	-0.53	-2.11	0.003
KRAS_SIGNALING_UP	16	-0.60	-1.97	0.004
ESTROGEN_RESPONSE_EARLY	32	-0.41	-1.67	0.027
Upregulated in Mesenchymal cells				
EPITHELIAL_MESENCHYMAL_TRANSITION	64	0.60	2.86	0.000
HYPOXIA	17	0.70	2.37	0.000
UV_RESPONSE_DN	16	0.69	2.35	0.000

Table 5 : REACTOME categories enriched in epithelial and mesenchymal cells. Categories that are mentionned all present a FDR-corrected q-value <0.05

REACTOME CATEGORY	SIZE	ES	NES	FDR q-val
Upregulated in Epithelial cells				
KERATINIZATION	21	-0,63	-2,30	0,001
FORMATION OF THE CORNIFIED ENVELOPE	21	-0,63	-2,29	0,000
Upregulated in Mesenchymal cells				
EXTRACELLULAR MATRIX ORGANIZATION	47	0,50	2,26	0,003
DISEASES OF GLYCOSYLATION	12	0,68	2,08	0,012
DISEASES OF METABOLISM	13	0,65	2,07	0,009
NERVOUS SYSTEM DEVELOPMENT	32	0,48	1,93	0,033
GLYCOSAMINOGLYCAN METABOLISM	11	0,64	1,88	0,041
A TETRASACCHARIDE LINKER SEQUENCE IS REQUIRED FOR GAG SYNTHESIS	8	0,70	1,86	0,041
HEPARAN SULFATE HEPARIN HS GAG METABOLISM	8	0,70	1,85	0,036
METABOLISM OF CARBOHYDRATES	13	0,59	1,84	0,035
NCAM SIGNALING FOR NEURITE OUT GROWTH	8	0,68	1,81	0,044
ELASTIC FIBRE FORMATION	12	0,59	1,81	0,041
ECM PROTEOGLYCANS	18	0,52	1,78	0,042

Table 6 : Chemical and Genetic Perturbations categories enriched in epithelial and mesenchymal cells. Categories that are mentionned all present a FDR-corrected q-value <0.05

CHEMICAL AND GENETIC PERTURBATIONS	SIZE	ES	NES	FDR q-val
Upregulated in Epithelial cells				
ONDER_CDH1_TARGETS_2_DN	145	-0,77	-4,30	0,000
CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP	73	-0,70	-3,50	0,000
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP	45	-0,78	-3,39	0,000
COLDREN_GEFITINIB_RESISTANCE_DN	59	-0,72	-3,35	0,000
HOLLERN_EMT_BREAST_TUMOR_DN	45	-0,73	-3,23	0,000
JAEGER_METASTASIS_DN	64	-0,64	-3,10	0,000
WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2_UP	22	-0,75	-2,77	0,000
WAMUNYOKOLI_OVARIAN_CANCER_LMP_UP	34	-0,64	-2,65	0,000
LIM_MAMMARY_STEM_CELL_DN	37	-0,61	-2,60	0,000
AIGNER_ZEB1_TARGETS	22	-0,68	-2,49	0,000
Upregulated in Mesenchymal cells				
ONDER_CDH1_TARGETS_2_UP	91	0,75	3,94	0,000
BOQUEST_STEM_CELL_UP	45	0,70	3,11	0,000
CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_DN	78	0,61	3,09	0,000
SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_UP	65	0,62	3,04	0,000
CHICAS_RB1_TARGETS_CONFLUENT	81	0,55	2,83	0,000
MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_DN	38	0,64	2,76	0,000
LINDGREN_BLADDER_CANCER_CLUSTER_2B	52	0,60	2,74	0,000
GU_PDEF_TARGETS_UP	23	0,73	2,72	0,000
PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP	33	0,67	2,71	0,000
CHICAS_RB1_TARGETS_GROWING	27	0,67	2,60	0,000

Table 7 : Gene Ontology categories enriched in epithelial and mesenchymal cells. Categories that are mentionned all present a nominal p-value <0.05 (except for cadherin binding)

GENE ONTOLOGY_CELL COMPONENT	SIZE	ES	NES	NOM p-val
Upregulated in Epithelial cells				
BASAL_PART_OF_CELL	30	-0.46	-1.83	0.002
BASOLATERAL_PLASMA_MEMBRANE	25	-0.46	-1.72	0.018
CELL_CELL_JUNCTION	65	-0.35	-1.69	0.004
APICAL_PART_OF_CELL	35	-0.41	-1.67	0.015
TIGHT_JUNCTION	21	-0.47	-1.67	0.020
INTERMEDIATE_FILAMENT_CYTOSKELETON	15	-0.49	-1.62	0.024
APICAL_JUNCTION_COMPLEX	27	-0.40	-1.57	0.024
PERINUCLEAR_REGION_OF_CYTOPLASM	42	-0.36	-1.56	0.030
Upregulated in Mesenchymal cells				
EXTERNAL_ENCAPSULATING_STRUCTURE	62	0.58	2.86	0.000
COLLAGEN_CONTAINING_EXTRACELLULAR_MATRIX	54	0.58	2.69	0.000
ENDOPLASMIC_RETICULUM_LUMEN	33	0.46	1.90	0.000
POSTSYNAPSE	29	0.46	1.80	0.004
SYNAPSE	59	0.36	1.71	0.000
NEURON_TO_NEURON_SYNAPSE	18	0.49	1.68	0.018
NEURON_PROJECTION	52	0.32	1.50	0.021

GENE ONTOLOGY_MOLECULAR FUNCTION	SIZE	ES	NES	NOM p-val
Upregulated in Epithelial cells				
ATP_DEPENDENT_ACTIVITY	15	-0.61	-1.99	0.002
CADHERIN_BINDING	22	-0.42	-1.53	0.054
Upregulated in Mesenchymal cells				
EXTRACELLULAR_MATRIX_STRUCTURAL_CONSTITUENT	27	0.62	2.40	0.000
GLYCOSAMINOGLYCAN_BINDING	27	0.54	2.13	0.000
STRUCTURAL_MOLECULE_ACTIVITY	58	0.38	1.79	0.010
SULFUR_COMPOUND_BINDING	27	0.46	1.77	0.004
IDENTICAL_PROTEIN_BINDING	86	0.33	1.73	0.002
ZINC_ION_BINDING	28	0.43	1.71	0.010
TRANSITION_METAL_ION_BINDING	38	0.38	1.61	0.020
CALCIUM_ION_BINDING	49	0.34	1.58	0.019
PROTEIN_HOMODIMERIZATION_ACTIVITY	37	0.36	1.52	0.035

GENE ONTOLOGY_BIOLOGICAL PATHWAY	SIZE	ES	NES	NOM p-val
Upregulated in Epithelial cells				
EPIDERMIS_DEVELOPMENT	35	-0.66	-2.72	0.000
EPIDERMAL_CELL_DIFFERENTIATION	24	-0.68	-2.60	0.000
KERATINOCYTE_DIFFERENTIATION	18	-0.69	-2.35	0.000
SKIN_DEVELOPMENT	34	-0.52	-2.15	0.000
SENSORY_PERCEPTION	22	-0.51	-1.84	0.002
EPITHELIAL_CELL_DEVELOPMENT	25	-0.47	-1.77	0.010
INTRACELLULAR_PROTEIN_TRANSPORT	26	-0.46	-1.76	0.015
MULTICELLULAR_ORGANISMAL_HOMEOSTASIS	28	-0.45	-1.75	0.012
CELL_CELL_JUNCTION_ORGANIZATION	26	-0.45	-1.71	0.010
EPITHELIAL_CELL_DIFFERENTIATION	67	-0.35	-1.69	0.004
Upregulated in Mesenchymal cells	**SIZE**	**ES**	**NES**	**NOM p-val**
EXTERNAL_ENCAPSULATING_STRUCTURE_ORGANIZATION	35	0.53	2.17	0.000
CELL_GROWTH	26	0.56	2.10	0.000
RESPONSE_TO_TRANSFORMING_GROWTH_FACTOR_BETA	20	0.57	2.05	0.000
TRANSFORMING_GROWTH_FACTOR_BETA_RECEPTOR_SIGNALIN G_PATHWAY	16	0.60	2.00	0.004
CELLULAR_COMPONENT_MORPHOGENESIS	37	0.47	1.99	0.000
SKELETAL_SYSTEM_DEVELOPMENT	39	0.45	1.93	0.002
REGULATION_OF_CELL_SUBSTRATE_ADHESION	23	0.51	1.92	0.004
REGULATION_OF_NEURON_PROJECTION_DEVELOPMENT	29	0.48	1.87	0.002
HEART_DEVELOPMENT	37	0.44	1.86	0.002
CIRCULATORY_SYSTEM_DEVELOPMENT	78	0.36	1.86	0.000

Supplementary data for Hullo et al.

Supplementary table 1. AuNP-NH2 features in H_2O or culture medium. Measures were performed with a Zetasizer equipement, and analysed with the Malvern Zetasizer software, in triplicates.

	Z-average in nm (H20)	Z-average in nm (DMEM)	Zeta Potential mV	Surface
AuNP-NH2 Batch 1	27,75	30,20	+23,2	PEG-NH2
AuNP-NH2 Batch 2	30,14	31,58	+14,8	PEG-NH2

Supplementary table 2. TiO_2 nanoparticles size measurements in H_20. Measures were performed with a Zetasizer equipement, and analysed with the Malvern Zetasizer software, in triplicates.

	NP Size	Z-average in nm (H20)
TiO_2 NM100	110 nm	300 nm +- 60
TiO_2 NM103	25 nm	233 nm +- 50



Supplementary figure 1 : SSC-A deviation signals from HMLE-E and HMLE-M cells exposed to NM103 TiO_2 NPs at a concentration of 10µg/cm². Cells were plated in 24 wells plates at 3 different plating densities (10.000, 30.000 or 45.000 cells, corresponding respectively to low, medium and high levels of confluence) and exposed to NPs 24h later. After 48h exposure suspensions were subjected to flow cytometry analysis. The graph represents the mean of data from 10000 cells, analysed in duplicates. Errors bars are SDs. The statistical significance was determined by using an ordinary one-way Anova test, and Sidaks' multiple comparisons test. Note: *** $p < 0.0005$ and ** $p < 0.005$.